While SUSTAIN-6 and REWIND trials examined GLP-1 RA in diabetics with different cardiovascular risk profile, The Harmony Outcomes study enrolled patients with T2D and established atherosclerotic cardiovascular disease (ASCVD). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.